GlassScriptPhysician profile
Lee C Drinkard
NPI 1487757084
$11,963.96
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,032 · 2020: $260 · 2021: $393 · 2022: $7,076 · 2023: $2,168 · 2024: $34.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.59 |
| Education | $114.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $6,331.40 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $923.36 | 2019-2023 | Lynparza |
| Pfizer INC. | $444.49 | 2019-2023 | |
| Daiichi Sankyo INC. | $378.57 | 2019-2024 | Injectafer, Enhertu |
| Seagen INC. | $283.69 | 2019-2023 | Tivdak, Adcetris, Tukysa |
| Amgen INC. | $246.09 | 2019-2022 | |
| Celgene Corporation | $238.59 | 2019-2023 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $222.82 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $202.27 | 2019-2023 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $170.45 | 2019-2023 | Opdualag |
| Novocure INC. | $166.79 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $161.91 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $158.96 | 2022-2023 | |
| Incyte Corporation | $152.69 | 2019 | |
| Genzyme Corporation | $151.93 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Drinkard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.